Related Experiment Video
Updated: Mar 9, 2026

Sequential Salt Extractions for the Analysis of Bulk Chromatin Binding Properties of Chromatin Modifying Complexes
Published on: October 2, 2017
BET Bromodomain Proteins as Cancer Therapeutic Targets
Shaokun Shu1, Kornelia Polyak1
1Department of Medical Oncology, Dana-Farber Cancer Institute; Department of Medicine, Brigham and Women's Hospital; and Department of Medicine, Harvard Medical School, Boston, Massachusetts 02215.
Abstract:
Epigenetic regulators are emerging therapeutic targets in a wide variety of human cancers. BET bromodomain proteins have been identified as key regulators of oncogenic transcription factors including MYC; therefore, their inhibition might provide a way to block these "undruggable" targets. Several BET bromodomain inhibitors are in clinical development with promising preliminary findings. However, tumors acquire resistance to these agents in several different ways. In this review, we summarize the role that BET bromodomain proteins play in tumorigenesis as well as the molecular mechanisms underlying therapeutic responses and resistance to their inhibition with emphasis on BRD4 and breast cancer.
Insights
BET bromodomain inhibitors show promise for treating cancers by targeting oncogenic transcription factors. However, understanding resistance mechanisms is crucial for effective cancer therapy.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Epigenetic regulators are key targets in cancer therapy.
- BET bromodomain proteins regulate oncogenic transcription factors like MYC.
- Inhibiting BET proteins offers a strategy against
Purpose of the Study:
- Review the role of BET bromodomain proteins in tumorigenesis.
- Summarize mechanisms of therapeutic response and resistance to BET inhibitors.
- Focus on BRD4 and breast cancer.
Main Methods:
- Literature review of epigenetic regulators in cancer.
- Analysis of BET bromodomain protein function.
- Examination of clinical development and resistance mechanisms of BET inhibitors.
Main Results:
- BET bromodomain inhibitors are in clinical trials with promising results.
- Tumors develop diverse resistance mechanisms to BET inhibitors.
- BRD4 plays a significant role in breast cancer.
Conclusions:
- BET bromodomain inhibition is a viable therapeutic strategy for various cancers.
- Further research into resistance mechanisms is essential for optimizing BET inhibitor efficacy.
- BRD4 and BET proteins are critical in breast cancer development and treatment.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Abnormal Proliferation
Mitogens and the Cell Cycle
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Canonical Wnt Signaling Pathway

